Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
Abstract Multiple myeloma (MM) treatment guidelines recommend waiting for formal progression criteria (FPC) to be met before proceeding to the next line of therapy. As predicting progression may allow early switching to next‐line therapy while the disease burden is relatively low, we evaluated the p...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13225 |